Pancreatic cancer is one of the most lethal cancer types. Enhancer of zeste homolog 2 (EZH2) is an oncogenic protein over-expressed in pancreatic cancer, and EZH2 could be a potential therapeutic target for the treatment of pancreatic cancer. Although significant progress has been made toward understanding the function and deregulation of EZH2 in cancer cells, the posttranslational regulation of EZH2 in cancer cells is still unclear. F-box and WD repeat domain-containing 7 (FBW7) acts as a tumor suppressor by targeting multiple oncoprotein substrates for ubiquitination and degradation. Here we demonstrate that EZH2 is a bona fide substrate of FBW7 in pancreatic cancer cells. We provide evidence that the activated CDK5 kinase is involved in the EZH2 phosphorylation that is required for FBW7-mediated degradation. We further show that FBW7 suppresses EZH2 activity and inhibits tumor migration and invasion via degradation of EZH2 in pancreatic cancer cells. Furthermore, immunohistochemistry analysis revealed that expression of EZH2 protein negatively correlates with FBW7 protein levels in a cohort of human pancreatic cancer specimens. Collectively, our findings demonstrate that FBW7 is a novel E3 ligase of EZH2 that regulates the EZH2 protein level in pancreatic cancer and represents a viable strategy for effective treatment of pancreatic cancer.

CDK5/FBW7-dependent ubiquitination and degradation of EZH2 inhibits pancreatic cancer cell migration and invasion

Received for publication, October 24, 2016, and in revised form, February 13, 2017 Published, JBC Papers in Press, February 27, 2017, DOI 10.1074/jbc.M116.764407

Xin Jin1, Chong Yang1, Ping Fan2, Jun Xiao2, Wanli Zhang2, Sudong Zhan2, Tao Liu2, Dejie Wang1, and Heshui Wu2
From the Departments of 1Digestive Surgical Oncology and 2Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China, the 3Organ Transplantation Center, Hospital of the University of Electronic Science and Technology of China and Sichuan Provincial People’s Hospital, Chengdu, Sichuan 610072, China, and the 4Department of Gastroenterology, Jiangxi Institute of Gastroenterology and Hepatology, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China

Edited by George N. DeMartino

This work was supported in part by grants from the National Natural Science Foundation of China (31560320 to D. W.), the Natural Science Foundation of Jiangxi Province (20142BAB215049 to D. W.), and the Scientific Research Foundation of China (31560320 to D. W.), the Natural Science Foundation of Jiangxi Province (20142BAB215049 to D. W.), and the Natural Science Foundation of China (31560320 to D. W.), the Natural Science Foundation of China (31560320 to D. W.), and the Natural Science Foundation of China (31560320 to D. W.).

1 The abbreviations used are: PDAC, pancreatic ductal adenocarcinoma; WD repeat domain-containing 7 (FBW7); H3K27, lysine 27 of histone 3; SCF, Skp1-Cull1-F-box; CbpD, Cdc4 phosphodegron; IP, immunoprecipitation; IS, immunoreactivity score; WCL, whole-cell lysate; CHX, cycloheximide; WB, Western blotting; RT-qPCR, quantitative real-time PCR.

Pancreatic cancer is one of the most lethal cancer types. The most common type of pancreatic cancer is adenocarcinoma (accounting for 95%), which originates from the exocrine part of the pancreas and is classified as pancreatic ductal adenocarcinoma (PDAC). PDAC is insensitive to both chemotherapy and radiotherapy (1). The prognosis for pancreatic cancer remains poor, with only 4.4% having a 5-year survival rate, making it the fourth leading cause of all cancer deaths in China (2). Thus, there is an immediate need to discover novel therapeutic targets for pancreatic cancer.

Aberrations of epigenetic regulation play an important role in the initiation and progression of cancers; therefore, the biochemical mediators of these processes could serve as novel and efficacious therapeutic targets (3–5). Enhancer of zeste homolog 2 (EZH2), a histone methyltransferase, interacts with other Polycomb-group (PcG) proteins such as SUZ12 and embryonic ectodomain development (EED), to form a protein complex called Polycomb repressive complex 2 (PRC2) (6). In many types of cancer cells, EZH2 epigenetically represses tumor suppressor gene expression through trimethylating H3K27 in order to mediate cell proliferation, invasion, and migration (7, 8). Moreover, EZH2 is highly expressed in many types of solid tumors, such as pancreatic cancer, and its higher expression is associated with a poor outcome (8, 9). It has been shown previously that EZH2 expression is regulated by the RB-E2F1 pathway (10) or by sex hormones such as androgens (11). Moreover, EZH2 is also regulated by microRNAs such as miR101 (12). Although significant progress has been made toward understanding the function and deregulation of EZH2 in cancer cells, the posttranslational regulation of EZH2 in cancer cells is still unclear.

F-box and WD repeat domain-containing 7 (FBW7), the substate recognition component of the Skp1-Cull1-F-box (SCF) ubiquitin ligase complex, binds to phosphorylated substrates within conserved phosphodegron motifs called Cdc4 phosphodegrons (CPDs) (13). FBW7 functions as a tumor suppressor by targeting multiple oncoprotein substrates for ubiquitination and degradation, including cyclin E, c-Myc, c-Jun, Notch-1, and SREBP1 (14–19). Disregulation of FBW7 has been proposed to drive the progression of pancreatic cancer (20).

In this study, we demonstrated that FBW7 acted as an E3 ligase of EZH2 in pancreatic cancer cells and found that the activated CDK5 kinase was involved in the EZH2 phosphorylation that was required for FBW7-mediated EZH2 degradation. Furthermore, we showed that EZH2 and FBW7 protein levels are negatively correlated in pancreatic cancer patient specimens. Taken together, these results are contributing to a better understanding of the regulatory mechanism of EZH2 in human...
FBW7 degrades EZH2 in pancreatic cancer

Results

FBW7 interacts with EZH2 in pancreatic cancer cells

The FBW7-binding consensus motif (T/S)PXX(S/T/D/E) has been identified in several FBW7 substrates, including cyclin E, c-Myc, c-Jun, Notch-1, and SREBP1 (14–19). We performed a protein motif search and discovered that EZH2 harbors one perfectly matched (261TPNID265) FBW7-binding motif (Fig. 1, A and B). Then we examined the basal protein levels of EZH2 and FBW7 in PANC-1 and MIA PaCa-2 cells (Fig. 1C). We found that there was a higher expression level of EZH2 but a lower expression level of FBW7 in MIA PaCa-2 cells compared with PANC-1 cells, which indicates that EZH2 might negatively correlate with FBW7 expression in these two cell lines.

This observation prompted us to investigate whether FBW7 functions as an E3 ubiquitin ligase of EZH2. Because substrate binding is a key event for E3 ligase-mediated ubiquitination and subsequent proteasome degradation, we first examined the interaction of FBW7 with EZH2 by using coimmunoprecipitation (co-IP) assay. Ectopically expressed FLAG-EZH2 protein was coimmunoprecipitated by Myc-FBW7. A similar result was obtained in a reciprocal co-IP experiment using FLAG antibody (Fig. 1D). Furthermore, the interaction between endogenous EZH2 and FBW7 in PANC-1 cells was confirmed by reciprocal
co-IP assays (Fig. 1E). To test which fragment of EZH2 is involved in FBW7 binding, we generated four GST-EZH2 recombinant proteins (Fig. 1F) (21, 22). GST pulldown assays showed that FBW7 specifically interacted with GST-EZH2-2 (252–384) but not the other three truncation mutants of EZH2 or GST alone in the lysates of PANC-1 cells (Fig. 1G). These data suggest that FBW7 interacts with EZH2 in pancreatic cancer cells.

**EZH2 is a substrate of FBW7 in pancreatic cancer cells**

FBW7α is the dominant isoform of FBW7 (23). To investigate whether FBW7 functions as an E3 ubiquitin ligase of EZH2 in pancreatic cancer, we co-transfected EZH2 with increasing amounts of FBW7α in PANC-1 pancreatic cancer cells. Ectopically expressed EZH2 was down-regulated by co-expression of FBW7, and this effect was completely blocked by treatment with the proteasome inhibitor MG132 (Fig. 2A), which indicates that FBW7 decreased EZH2 protein levels via the proteasome pathway. To test the effect of FBW7 on endogenous EZH2 in pancreatic cancer cells, we performed knockdown of endogenous FBW7 by two independent FBW7-specific shRNAs, which increased EZH2 protein levels (Fig. 2B) and had no effect on EZH2 mRNA levels (Fig. 2C) in both PANC-1 and MIA PaCa-2 pancreatic cancer cells. Importantly, knockdown of FBW7 prolonged the half-life of endogenous EZH2 protein in PANC-1 cells (Fig. 2, D and E). Furthermore, PANC-1 cells were transfected with three isoforms (α, β, and γ) of FBW7 individually, resulting in a marked reduction in the protein level of EZH2 in a dose-dependent manner (Fig. 2F). FBW7 is the substrate-binding subunit of the SCFFBW7 ubiquitin ligase complex, and the F-box domain is essential for its E3 ligase activity (24). As shown in Fig. 2G, wild-type FBW7α, but not the FBW7αΔ F-box mutant, promoted EZH2 degradation. Furthermore, we found that knockdown of endogenous FBW7 in PANC-1 cells decreased the polyubiquitination of endogenous EZH2 (Fig. 2H). Meanwhile, EZH2 was polyubiquitinated by co-expression of wild-type FBW7α but not the enzymatically dead mutant (FBW7αΔ F-box) in a dose-dependent manner (Fig. 2I). Together, these data demonstrate that FBW7 promotes EZH2 protein ubiquitination and proteasome degradation in pancreatic cancer cells.

**FBW7-mediated degradation of EZH2 is Thr261-dependent**

FBW7 often recognizes phosphorylated Ser/Thr residues in the CPD motif of the FBW7 target proteins by corresponding kinase, including GSK3β (25), CDK1/2 (26), or CDK5 (27), is required for FBW7-mediated degradation. To determine which kinase is involved in the phosphorylation of Thr261, we first checked the amino acid sequence in EZH2 and found that Thr261 in EZH2 did not match the general CDK1/2 consensus motif (S/TPxK/R) (26). Of note, knockdown of the endogenous GSK3β by shRNA or the treatment with a selective GSK3β inhibitor, LiCl, could not abrogate the degradation process of EZH2 induced by FBW7 (endogenous c-myc as a positive control) (supplemental Fig. 1, A and B). These results indicated that GSK3β was not likely to be the kinase involved in FBW7-mediated degradation of EZH2. We speculated that the Thr261 of EZH2 might be phosphorylated by CDK5 and then recognized by FBW7. To test whether CDK5 induces degradation of EZH2, overexpression of CDK5 or p35, an activator of CDK5, could not decrease the protein level of wild-type EZH2, but co-transfection with CDK5 and p35 resulted in down-regulation of wild-type EZH2, and this process was blocked by the proteasome inhibitor MG132 (Fig. 4, A and B). Furthermore, the dominant-negative mutant of CDK5 (CDK5 D145N) (27) could not decrease the protein level of EZH2 compared with wild-type CDK5 (Fig. 4C). Importantly, co-overexpression of CDK5 and p35 only led to down-regulation of wild-type EZH2, shortening the half-life and promoting polyubiquitination of wild-type EZH2 but not the EZH2 T261A mutant (Fig. 4, D–G). Together, these results suggest that activated CDK5 induces degradation of wild-type EZH2 and, at least, is involved in phosphorylation of Thr261 in EZH2.

**FBW7 suppresses EZH2 activity in pancreatic cancer cells**

To evaluate the biological consequences of FBW7-mediated EZH2 degradation, we examined the effect of FBW7 on the transactivation of EZH2 target genes. It is known that EZH2 represses gene expression in a Polycomb-dependent way, and such target genes include FOXJ1, HOXA9, and BRACHYURY (6). In addition to the canonical Polycomb-dependent gene repression function, EZH2 also gains a Polycomb-independent gene activation function and promotes the gene expression of TMEM48 and CSK2 (28). As expected, knockdown of EZH2 by specific shRNAs increased the protein expression of FOXJ1, HOXA9, and BRACHYURY and down-regulated TMEM48 and CSK2 expression in PANC-1 cells. Intriguingly, the effect of EZH2 appears to be specific because restored expression of shRNA-resistant EZH2 by EZH2-WT or EZH2 T261A reversed the EZH2 knockdown-induced effect in its target genes, whereas knockdown of FBW7 was shown to restore the role of EZH2 in these genes activities (Fig. 5, A–D). To further test the role of FBW7 in EZH2 activity, we transfected EZH2 alone and co-expressed wild-type FBW7α or the enzymatically dead mutant (FBW7αΔ F-box) together with EZH2 in PANC-1 cells.

**FBW7 degrades EZH2 in pancreatic cancer**

Phosphorylation of the first Ser/Thr in the CPD motif of the FBW7 target proteins by corresponding kinase, including GSK3β (25), CDK1/2 (26), or CDK5 (27), is required for FBW7-mediated degradation. To determine which kinase is involved in the phosphorylation of Thr261, we first checked the amino acid sequence in EZH2 and found that Thr261 in EZH2 did not match the general CDK1/2 consensus motif (S/TPxK/R) (26). Of note, knockdown of the endogenous GSK3β by shRNA or the treatment with a selective GSK3β inhibitor, LiCl, could not abrogate the degradation process of EZH2 induced by FBW7 (endogenous c-myc as a positive control) (supplemental Fig. 1, A and B). These results indicated that GSK3β was not likely to be the kinase involved in FBW7-mediated degradation of EZH2. We speculated that the Thr261 of EZH2 might be phosphorylated by CDK5 and then recognized by FBW7. To test whether CDK5 induces degradation of EZH2, overexpression of CDK5 or p35, an activator of CDK5, could not decrease the protein level of wild-type EZH2, but co-transfection with CDK5 and p35 resulted in down-regulation of wild-type EZH2, and this process was blocked by the proteasome inhibitor MG132 (Fig. 4, A and B). Furthermore, the dominant-negative mutant of CDK5 (CDK5 D145N) (27) could not decrease the protein level of EZH2 compared with wild-type CDK5 (Fig. 4C). Importantly, co-overexpression of CDK5 and p35 only led to down-regulation of wild-type EZH2, shortening the half-life and promoting polyubiquitination of wild-type EZH2 but not the EZH2 T261A mutant (Fig. 4, D–G). Together, these results suggest that activated CDK5 induces degradation of wild-type EZH2 and, at least, is involved in phosphorylation of Thr261 in EZH2.

**FBW7 suppresses EZH2 activity in pancreatic cancer cells**

To evaluate the biological consequences of FBW7-mediated EZH2 degradation, we examined the effect of FBW7 on the transactivation of EZH2 target genes. It is known that EZH2 represses gene expression in a Polycomb-dependent way, and such target genes include FOXJ1, HOXA9, and BRACHYURY (6). In addition to the canonical Polycomb-dependent gene repression function, EZH2 also gains a Polycomb-independent gene activation function and promotes the gene expression of TMEM48 and CSK2 (28). As expected, knockdown of EZH2 by specific shRNAs increased the protein expression of FOXJ1, HOXA9, and BRACHYURY and down-regulated TMEM48 and CSK2 expression in PANC-1 cells. Intriguingly, the effect of EZH2 appears to be specific because restored expression of shRNA-resistant EZH2 by EZH2-WT or EZH2 T261A reversed the EZH2 knockdown-induced effect in its target genes, whereas knockdown of FBW7 was shown to restore the role of EZH2 in these genes activities (Fig. 5, A–D). To further test the role of FBW7 in EZH2 activity, we transfected EZH2 alone and co-expressed wild-type FBW7α or the enzymatically dead mutant (FBW7αΔ F-box) together with EZH2 in PANC-1 cells.
**FBW7 degrades EZH2 in pancreatic cancer**

It was consistent with the finding that overexpression of EZH2 decreased the protein level of FOXJ1, repressed HOXA9 and BRACHYURY expression, and activated TMEM48 and CSK2 expression (Fig. 5, E and F). Importantly, co-expression of FBW7α abrogated the effect of EZH2. In contrast, overexpression of FBW7α F-box had no obvious effect on the suppression of EZH2 activity. Thus, these data demonstrate that FBW7-mediated degradation of EZH2 negatively impacts its transactivation function in pancreatic cancer cells.

**FBW7 inhibits tumor migration and invasion via degradation of EZH2 in pancreatic cancer cells**

It is previously reported that EZH2 knockdown in pancreatic cancer cell lines inhibited cell migration and invasion but not...
proliferation (8, 29). We performed a cell proliferation assay after knocking down EZH2 and rescuing EZH2 by shRNA-resistant EZH2 wild-type or EZH2 T261A plasmids in PANC-1 and MIA PaCa-2 cells within 48 h (supplemental Fig. 1, C and D). The data also demonstrated that EZH2 had a subtle effect on altering cell proliferation in pancreatic cancer. To elucidate the biological function of FBW7 in mediating EZH2 degradation, we used a wound healing assay and transwell invasion assay to examine the effect on cell migration and invasion in pancreatic cancer cells. We observed that knockdown of EZH2 reduced migration and invasion activities in both PANC-1 and MIA PaCa-2 cells (Fig. 6, A–F), whereas restored expression of shRNA-resistant EZH2 by EZH2-WT or EZH2 T261A reversed the EZH2 knockdown-induced effect (Fig. 6, A–D). Moreover, knockdown of FBW7 alone increased migration and invasion activities, and FBW7 blocked the effect of EZH2 on cell migration and invasion when we knocked down both FBW7 and EZH2 (Fig. 6, E and H). Furthermore, we demonstrated that overexpression of EZH2 alone increased migration and invasion activity, and co-expression of wild-type FBW7α, but not the enzymatically dead mutant FBW7α Δ F-box, with EZH2 abrogated the effect of overexpression of EZH2 alone in both PANC-1 and MIA PaCa-2 cells (Fig. 6, I–L). Thus, these results indicate that FBW7 inhibits tumor cell migration via degradation of EZH2 in pancreatic cancer cells.

**EZH2 and FBW7 protein levels negatively correlate in human pancreatic cancer specimens**

It has been shown previously that EZH2 expression is up-regulated in pancreatic cancer tissues and that it correlates with a poor prognosis (8). However, FBW7 is down-regulated in pancreatic cancer tissues, and low expression of FBW7 is associated with high malignancy and a poor prognosis in pancreatic cancer cases (20). Thus, to investigate the clinical relevance of FBW7 and EZH2, we examined the expression of these proteins by immunohistochemistry in human pancreatic cancer specimens obtained from a cohort of patients (n = 10 normal pancreatic tissue specimens, n = 47 PDAC tissue specimens). Immunohistochemistry staining was evaluated by measuring both the percentage of positive cells and staining intensity. Examples of both strong and weak staining of FBW7 and EZH2 proteins staining are shown in Fig. 7A. PDAC tissues had lower expression of FBW7 (p = 4.91e−06) but a higher level of EZH2 (p = 7.62e−07) compared with the control group (n.s., not significant). D and E, PANC-1 cells were transfected with control and FBW7-specific shRNAs. After 48 h, cells were treated with 50 μg/μl cycloheximide (CHX). At different time points, cells were harvested for Western blotting analysis. As a loading control, we demonstrated that overexpression of EZH2 alone in both PANC-1 and MIA PaCa-2 cells (Fig. 6, I–L). Thus, these results indicate that FBW7 inhibits tumor cell migration via degradation of EZH2 in pancreatic cancer cells.

**EZH2 is a substrate of FBW7 in pancreatic cancer cells.** A, Western blotting analysis of WCLs of PANC-1 cells transfected with the indicated constructs. Cells were treated with or without 20 μM MG132 for 8 h before harvest. Data are representative of multiple experiments (n = 3). B, PANC-1 and MIA PaCa-2 cells were transfected with control or two independent FBW7-specific shRNAs. 48 h after transfection, cells were harvested for Western blotting analysis. Data are representative of multiple experiments (n = 3). C, PANC-1 cells were transfected with control or shRNAs as indicated. 48 h after transfection, cells were harvested for RT-qPCR analysis of EZH2 and FBW7 mRNAs. Data are mean ± S.D. from experiments with three replicates. *, p < 0.05 compared with the control group; n.s., not significant. D and E, PANC-1 cells were transfected with control and FBW7-specific shRNAs. After 48 h, cells were treated with 50 μg/μl cycloheximide (CHX). At different time points, cells were harvested for Western blotting analysis. At each time point, the intensity of EZH2 was normalized to the intensity of β-tubulin (loading control) first and then to the value at the 0-h time point. F, PANC-1 cells were transfected with the indicated plasmids for 24 h, followed by Western blotting analysis. Data are representative of multiple experiments (n = 3). G, PANC-1 cells were transfected with the indicated plasmids for 24 h, followed by Western blotting analysis. Data are representative of multiple experiments (n = 3). H, PANC-1 cells were transfected with the indicated plasmids for 48 h, followed by treatment with 20 μM MG132 for 8 h. Immunoprecipitated EZH2 proteins were analyzed by WB for ubiquitination. I, PANC-1 cells were transfected with the indicated plasmids for 16 h, followed by treatment with 20 μM MG132 for 8 h. Immunoprecipitated FLAG-EZH2 proteins were analyzed by WB for ubiquitination.

**Figure 2. EZH2 is a substrate of FBW7 in pancreatic cancer cells.** A, Western blotting analysis of WCLs of PANC-1 cells transfected with the indicated constructs. Cells were treated with or without 20 μM MG132 for 8 h before harvest. Data are representative of multiple experiments (n = 3). B, PANC-1 and MIA PaCa-2 cells were transfected with control or two independent FBW7-specific shRNAs. 48 h after transfection, cells were harvested for Western blotting analysis. Data are representative of multiple experiments (n = 3). C, PANC-1 cells were transfected with control or shRNAs as indicated. 48 h after transfection, cells were harvested for RT-qPCR analysis of EZH2 and FBW7 mRNAs. Data are mean ± S.D. from experiments with three replicates. *, p < 0.05 compared with the control group; n.s., not significant. D and E, PANC-1 cells were transfected with control and FBW7-specific shRNAs. After 48 h, cells were treated with 50 μg/μl cycloheximide (CHX). At different time points, cells were harvested for Western blotting analysis. At each time point, the intensity of EZH2 was normalized to the intensity of β-tubulin (loading control) first and then to the value at the 0-h time point. F, PANC-1 cells were transfected with the indicated plasmids for 24 h, followed by Western blotting analysis. Data are representative of multiple experiments (n = 3). G, PANC-1 cells were transfected with the indicated plasmids for 24 h, followed by Western blotting analysis. Data are representative of multiple experiments (n = 3). H, PANC-1 cells were transfected with the indicated plasmids for 48 h, followed by treatment with 20 μM MG132 for 8 h. Immunoprecipitated EZH2 proteins were analyzed by WB for ubiquitination. I, PANC-1 cells were transfected with the indicated plasmids for 16 h, followed by treatment with 20 μM MG132 for 8 h. Immunoprecipitated FLAG-EZH2 proteins were analyzed by WB for ubiquitination.
3.72e−06) compared with adjacent normal tissues (Fig. 7B). It was also shown that well differentiated tumors (G1) had higher FBW7 expression (p = 0.0188) compared with poorly differentiated tumors (G3). In contrast, well differentiated tumors had lower EZH2 expression (p = 0.0036) compared with poorly differentiated tumor (Fig. 7C). Moreover, the statistical analysis indicated that EZH2 was negatively correlated with FBW7 expression in this cohort (Pearson’s product-moment correla-
tion $r = -0.35, p = 0.00133$) (Fig. 7D). These data suggest that EZH2 and FBW7 protein levels are negatively correlated in human pancreatic cancer specimens.

**Discussion**

Epigenetic silencing of tumor suppressor genes mediated by aberrant DNA methylation and histone modification leads to uncontrolled proliferation in human cancer (9). EZH2 is a catalytic subunit of polycomb repressive complex 2 (PRC2), which represses tumor suppressor genes via trimethylation of lysine 27 of histone 3 (H3K27) (30). EZH2 is an oncogenic protein overexpressed in pancreatic cancer. Aberrant nuclear accumulation of EZH2 enhances tumorigenesis, promotes liver metastasis, and facilitates cancer stem cell maintenance in pancreatic cancer cells (31). Inhibition of EZH2 sensitizes pancreatic cancer to chemotherapy (32). Although significant progress has been made toward understanding the function and deregulation of EZH2 in cancer cells, there is little study of the modification of EZH2 after translation. In this study, we provide evidence that FBW7 interacts with EZH2 in pancreatic cancer cells and downregulated EZH2 via ubiquitination and degrada-
FBW7 degrades EZH2 in pancreatic cancer

A

B

C

D

E

F

G

H

I

J

K

L
tion, which indicated that FBW7 might play a significant role in the modification of EZH2.

FBW7, the substrate recognition component of the SCF ubiquitin ligase complex, functions as a tumor suppressor by targeting multiple oncoprotein substrates for ubiquitination and degradation. FBW7 substrates have a consensus FBW7-binding motif, (T/S)PXX(S/T/D/E), that mediates FBW7 recognition. Through motif analysis, we identified a perfectly matched FBW7-binding motif (261TPNID265) in EZH2. It is reported that up-regulation of EZH2 is correlated with a poor prognosis in pancreatic cancer cases (8). Moreover, low expression of FBW7 is relevant to a poor prognosis in pancreatic cancer (20). Thus, our study not only identifies EZH2 as a novel ubiquitination and degradation substrate of FBW7, and FBW7-mediated degradation of EZH2 negatively impacts its transactivation function and inhibits tumor migration in pancreatic cancer cells, but also demonstrates that EZH2 and FBW7 protein levels were negatively correlated in human pancreatic cancer specimens. To this end, these results suggest that down-regulation of FBW7, inducing high EZH2 protein levels, to some extent promoted tumor progression in pancreatic cancer.

Phosphorylation of the first Ser/Thr in the CPD motif of the FBW7 target proteins is essential for FBW7-mediated degradation. We provide evidence that FBW7-mediated degradation of EZH2 is Thr261-dependent. The majority of FBW7 substrates, such as c-jun and c-myc, are phosphorylated by GSK3β within their CPD motifs for recognition and subsequent ubiquitination by FBW7. Recently, Ko et al. (33) reported that GSK3β could interact with EZH2 and phosphorylate EZH2 at Ser363 and Thr367, which down-regulated H3K27 trimethylation and EZH2 oncogenic functions in breast cancer cells. Importantly, there was no change in EZH2 protein level after treatment with...
**FBW7 degrades EZH2 in pancreatic cancer**

The inhibitor of GSK3β or knockdown of endogenous GSK3β (33). Our results also demonstrated that knockdown of endogenous GSK3β or treatment of cells with LiCl could not abrogate the degradation process of EZH2 induced by FBW7. In addition, CDK1 and CDK2 could phosphorylate EZH2 at Thr300 and Thr301 (34), but these two sites do not match the FBW7-binding motif. In other words, phosphorylation of EZH2 at Thr261 might require another kinase. Maskey et al. (27) reported that CDK5 phosphorylated NDE1 within a specific FBW7 phosphodegron and induced down-regulation of NDE1. An important aspect of our findings is that activation of CDK5 via p35 induces degradation of wild-type EZH2 but not the EZH2 T261A mutant. Thus, our results demonstrate that CDK5 acts as the kinase that phosphorylates EZH2 at Thr261 and reduces its protein stability.

In summary, we identify that FBW7 is an E3 ubiquitin ligase of EZH2 and that its low expression contributes to an aberrant accumulation of EZH2 in pancreatic cancer. We discover that FBW7-mediated degradation of EZH2 is Thr261-dependent. Activated CDK5 phosphorylates EZH2 and promotes EZH2 degradation. These findings have revealed the important function of FBW7 in the regulation of the EZH2 protein level in pancreatic cancer, which might represent a viable strategy for the effective treatment of pancreatic cancer.

**Experimental procedures**

**Cell lines, cell culture, and treatment**

The pancreatic cancer cell lines PANC-1 and MIA PaCa-2 were purchased from the Chinese Academy of Science Cell Bank and cultured in a 5% CO2, 37 °C, and 95% humidity incubator. PANC-1 and MIA PaCa-2 cells were cultured in DMEM supplemented with 10% fetal bovine serum (Thermo Fisher Scientific). Transfections were performed using Lipofectamine 2000 (Invitrogen) according to the protocol of the manufacturer.

**Plasmids and reagents**

FLAG-EZH2 was cloned into the pcDNA3.0 vector. HA-p35, Myc-CDK5, and Myc-FBW7 were cloned into the pcMV vector. GST-EZH2 was cloned into the pGEX-4T-1 vector. Myc-FBW7 Δ F-box and Myc-CDK5 D145N were generated using the KOD-Plus mutagenesis kit (Toyobo). The antibodies used were FBW7 (Bethyl, 301-720A-1), EZH2 (Cell Signaling Technology, 5246S), c-myc (Santa Cruz Biotechnology, SC-40), anti-FLAG (Sigma-Aldrich, F-3165), and anti-HA (Covance, MMS-101R).

**Immunoprecipitation and Western blotting**

Briefly, cells were harvested and lysed by IP buffer (150 mM NaCl, 1% Nonidet P-40, 50 mM Tris-HCl (pH 7.5), 0.5% sodium deoxycholate, and 1% protease inhibitor cocktails, Sigma-Aldrich). Cell lysates were centrifuged for 15 min, and the supernatant was incubated with the indicated antibodies and protein G beads (Thermo Fisher Scientific) at 4 °C overnight. The beads were washed five times with IP buffer, and the precipitated proteins were subjected to further analysis. For Western blotting, cells were lysed by radioimmune precipitation assay buffer. Protein for each sample was separated by SDS-polyacrylamide gels and transferred onto nitrocellulose membranes. The membranes were immunoblotted with specific primary antibodies followed by horseradish peroxidase-conjugated secondary antibodies and visualized by SuperSignal West Pico stable peroxide solution (Thermo Scientific).

**RNA isolation, reverse transcription, and real-time PCR**

Total RNA was isolated from PDAC cells using TRIzol reagent (Thermo Fisher Scientific). Reverse transcription was performed using SuperScript® II reverse transcriptase (Thermo Fisher Scientific). RT-PCR was carried out on a QTX detection system (Bio-Rad). All reactions were performed in triplicate. The primers used were as follows: EZH2, 5′-CCCTGACCTCT-GTCTTACTTGTGGA-3′ (forward) and 5′-AGCTCAGATGGTGCAGAATATA-3′ (reverse); FBW7, 5′-CCACTGGGCT-TGTACCAGTT-3′ (forward) and 5′-CAGATGTAATT-CGCGTCTGTT-3′ (reverse); HOXA9, 5′-TTGAGGAAATGAATGCTGTA-3′ (forward) and 5′-TGTTGCAACAGCCT-TGA GGT-3′ (reverse); BRACHYURY, 5′-AGGTGGGG-AAGTTCTCTCTC-3′ (forward) and 5′-GCAAATAGGG-TCTTTTGTTG-3′ (reverse); TME4M, 5′-AGTGGGC-GGGACATCTGTG-3′ (forward) and 5′-TGCAAGATGGG-TAGAAAATAGCCT-3′ (reverse); CSK2, 5′-TTCGAGAACACTACGAGTACC-3′ (forward) and 5′-GGACACC-AAGTCCTCCTC CAC-3′ (reverse); and GAPDH, 5′-ACC-CACCTCCACCCTTTGAC-3′ (forward) and 5′-TGTT-GCTGTAGCCAAATTCGTT-3′ (reverse). GAPDH was used as an internal reference.

**RNA interference**

Lentivirus-based control and gene-specific shRNAs were purchased from Sigma-Aldrich. Transfections were performed according to the protocol of the manufacturer (Sigma-Aldrich). After infection, puromycin (0.5 µg/ml) was used to select stably transduced cells. shRNA sequences were as follows: shFBW7-1, CGGGGATGGGTTTTCTACGCGACATTACTCGAGTAAAGTGTCCGTAAGAAAACCCATTTTTTG; shFBW7-2, CGGGC-ATTGTTGAGCCGATATACCGAGATCTGCGTTACATACAAATGTTGTTGTT; shEZH2-1, CGGGGCTAGGTTGAATGCTGA-ATTTGAGACAAAACTCTTTGCTCCAATTAACCTAGTTTTTG; and shEZH2-2, CGGGGCAACACAGTCTACCCATTACTCGAGTAAATGGGATGACTTGTGGTTTTTG.

**In vitro migration assay**

Cells were transfected with the indicated plasmids and cultured to confluence on 6-well plates. The cell layer was scratched with a 200-µl pipette tip, and detached cells were removed. For each sample, at least three scratched fields were photographed immediately. Cell migration was evaluated by measuring the cell-covered area.

**In vitro invasion assay**

The in vitro cell invasion assay was performed using a Bio-Coat Matrigel invasion chamber (BD Biosciences) according to the protocol of the manufacturer. PANC-1 and MIA PaCa-2 cells were cultured in the insert for 24 h. Cells were fixed in methanol for 15 min and then stained with 1 mg/ml crystal
violet for 20 min. At least five fields for each group were photographed after staining, and invaded cells were counted.

**Tissue microarray and immunohistochemistry**

The tissue microarray slides were purchased from Biomax US (lot no. PA1001a). The immunohistochemistry staining was evaluated by two independent pathologists who were blinded to the clinical details. Based on the percentage of positive cells and the staining intensity (35), the final immunoreactivity score (IS) for each case was calculated as follows: staining percentage × intensity.

**Statistical analysis**

All data are expressed as means ± S.D. For experiments with only two groups, Student’s *t* test was used for statistical comparisons. For analysis of correlation between EZH2 and FBW7 protein expression in human pancreatic cancer specimens, Pearson’s product-moment correlation was used. *p* < 0.05 was considered statistically significant.

**Author contributions**—H. W. and D. W. conceived the study. X. J., P. F., C. Y., J. X., W. Z., and S. Z. performed the experiments. T. L., X. J., D. W., and H. W. wrote the paper.

**References**

1. The Lancet Oncology (2014) Pancreatic cancer in the spotlight. *Lancet Oncol.* **15**, 241
2. Long, J., Luo, G. P., Xiao, Z. W., Liu, Z. Q., Guo, M., Liu, L., Liu, C., Xu, J., Gao, Y. T., Zheng, Y., Wu, C., Ni, Q. X., Li, M., and Yu, X. (2014) Cancer statistics: current diagnosis and treatment of pancreatic cancer in Shanghai, China *Cancer Lett.* **346**, 273–277
3. Rodríguez-Paredes, M., and Esteller, M. (2011) Cancer epigenetics reaches mainstream oncology. *Nat. Med.* **17**, 330–339
4. Chi, P., Allis, C. D., and Wang, G. G. (2010) Covalent histone modifications: miswritten, misinterpreted and mis-erased in human cancers. *Nat. Rev. Cancer* **10**, 457–469
5. Tzatsos, A., Paskaleva, P., Ferrari, F., Deshpande, V., Stoykova, S., Contino, G., Wong, K. K., Lan, F., Trojer, P., Park, P. J., and Bardeesy, N. (2013) KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs. *J. Clin. Invest.* **123**, 727–739
6. Chen, S., Boher, L. R., Rai, A. N., Pan, Y., Gan, L., Zhou, X., Bagchi, A., Simon, J. A., and Huang, H. (2010) Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. *Nat. Cell Biol.* **12**, 1108–1114
7. Simon, J. A., and Kingston, R. E. (2009) Mechanisms of polycomb gene association with MALAT-1 in pancreatic cancer.
8. Ougolkov, A. V., Bilim, V. N., and Billadeau, D. D. (2008) Regulation of prostate cancer. *Nat. Rev. Mol. Cell Biol.* **9**, 83–93
9. Kumar, Y., Kapoor, L., Khan, K., Thacker, G., Khan, M. P., Shukla, N., Kanaujia, J. K., Sanyal, S., Chattopadhyay, N., and Trivedi, A. K. (2015) E3 ubiquitin ligase Fbw7 Negatively regulates osteoblast differentiation by targeting Runx2 for degradation. *J. Biol. Chem.* **290**, 10368–10381
10. Fukushima, T., Ando, T., Kato, T., Ishikawa, N., and Kitagawa, M. (2015) Regulation of GATA-binding protein 2 phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7). *Cell Metab.* **1**, 379–391
11. Gupta-Rossi, N., Le Bail, O., Gonen, H., Brou, C., Logeat, F., Six, E., Ciechanover, A., and Israel, A. (2001) Functional interaction between SEL-10, an F-box protein, and the nuclear form of activated Notch1 receptor. *J. Biol. Chem.* **276**, 34371–34378
12. Wang, D., Ding, L., Wang, L., Zhao, Y., Sun, Z., Karnes, R. J., Zhang, H., and Huang, H. (2015) LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer. *Oncotarget* **6**, 41045–41055
13. Welcker, M., and Clurman, B. E. (2008) FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. *Nature* **457**, 984–989
14. Welcker, M., Orian, A., Jin, J., Grim, J. E., Grim, J. A., Harper, J. W., and Ericsson, J. (2005) Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7). *Cell Metab.* **1**, 379–391
15. Gupta-Rossi, N., Le Bail, O., Gonen, H., Brou, C., Logeat, F., Six, E., Ciechanover, A., and Israel, A. (2001) Functional interaction between SEL-10, an F-box protein, and the nuclear form of activated Notch1 receptor. *J. Biol. Chem.* **276**, 34371–34378
16. Nateri, A. S., Riera-Sans, L., Da Costa, C., and Behrens, A. (2004) The ubiquitin ligase SCFbw7 antagonizes apoptotic JNK signaling. *Science* **305**, 1374–1378
17. Welcker, M., and Clurman, B. E. (2008) FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. *Nature* **457**, 893–943
18. Han, T., Jiao, F., Hu, H., Zhou, H., Gao, J., Zhang, B., Xu, W., Liu, J., Liang, D., Liu, L., Liu, C., Long, J., Zhou, H., et al. (2015) ERK kinase phosphatases and destabilizes the tumor suppressor FBW7 in pancreatic cancer. *Cell Res.* **25**, 561–573
19. Kaneko, S., Li, G., Son, J., Xu, C. F., Margueron, R., Neubert, T. A., and Reinberg, D. (2010) Phosphorylation of the PRC2 component EZH2 is cell cycle-regulated and up-regulates its binding to ncRNA. *Genes Dev.* **24**, 2615–2620
20. Wang, D., Ding, L., Wang, L., Zhao, Y., Sun, Z., Karnes, R. J., Zhang, H., and Huang, H. (2015) LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer. *Oncotarget* **6**, 41045–41055
21. Vinay, N., Roy, S., and Roy, A. (2006) EZH2 degrades positive regulators of cell proliferation. *Curr. Med. Chem.* **13**, 961–970
22. Li, S., Qin, Y., Shi, S., Liu, X., Hu, H., Zhou, H., Gao, J., Zhang, B., Xu, W., Liu, J., Liang, D., Liu, L., Liu, C., Long, J., Zhou, H., et al. (2015) ERK kinase phosphatases and destabilizes the tumor suppressor FBW7 in pancreatic cancer. *Cell Res.* **25**, 561–573
30. Reijm, E. A., Timmermans, A. M., Look, M. P., Meijer-van Gelder, M. E., Stobbe, C. K., van Deurzen, C. H., Martens, J. W., Sleijfer, S., Foekens, J. A., Berns, P. M., and Jansen, M. P. (2014) High protein expression of EZH2 is related to unfavorable outcome to tamoxifen in metastatic breast cancer. Ann Oncol. 25, 2185–2190

31. Chen, Y., Xie, D., Yin Li, W., Man Cheung, C., Yao, H., Chan, C. Y., Chan, C. Y., Xu, F. P., Liu, Y. H., Sung, J. J., and Kung, H. F. (2010) RNAi targeting EZH2 inhibits tumor growth and liver metastasis of pancreatic cancer in vivo. Cancer Lett. 297, 109–116

32. Cao, Q., Yu, J., Dhanasekaran, S. M., Kim, J. H., Mani, R. S., Tomlins, S. A., Mehra, R., Laxman, B., Cao, X., Kleer, C. G., Varambally, S., and Chinnaiyan, A. M. (2008) Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 27, 7274–7284

33. Ko, H. W., Lee, H. H., Huo, L., Xia, W., Yang, C. C., Hsu, J. L., Li, L. Y., Lai, C. C., Chan, L. C., Cheng, C. C., Labaff, A. M., Liao, H. W., Lim, S. O., Li, C. W., Wei, Y., et al. (2016) GSK3β inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers. Oncotarget 7, 57131–57144

34. Wei, Y., Chen, Y. H., Li, L. Y., Lang, J., Yeh, S. P., Shi, B., Yang, C. C., Yang, J. Y., Lin, C. Y., Lai, C. C., and Hung, M. C. (2011) CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Nat. Cell Biol. 13, 87–94

35. Jin, X., Tian, S., and Li, P. (2016) Histone acetyltransferase 1 promotes cells proliferation and induces cisplatin resistance in hepatocellular carcinoma. Oncol. Res., in press